# Antheia gets $80 million conditional Pentagon loan commitment for U.S. drug-ingredient production
The financing would help establish U.S. manufacturing for ingredients Antheia now produces through overseas partners. The company must meet additional requirements before financial close.
Published 2026-10-18 by TGOs. Canonical: https://tgos.io/news/2026/10/18/antheia-gets-80-million-conditional-pentagon-loan-commitment-for/
The Department of War’s Office of Strategic Capital announced an $80 million conditional loan commitment to support Antheia’s U.S. production of ingredients for generic drugs.[1] The financing, alongside additional private capital, is intended to help establish domestic manufacturing operations.[1]
Antheia currently produces its pipeline of key starting materials and active pharmaceutical ingredients through contract manufacturing partners abroad.[1] It uses bioengineered yeast to convert sugar directly into those ingredients for essential medicines in a one-step fermentation process.[1][2]
Before financial close, Antheia must meet financial, legal, technical, investment, due diligence and other requirements.[1]
## Why it matters
The department says the vast majority of key starting materials and active pharmaceutical ingredients are manufactured outside the United States.[1] It says establishing Antheia’s U.S. operations would help onshore essential medicine supply chains and ultimately reduce the risk of shortages.[1]
## Sources
1. Department of War release: Office of Strategic Capital signs $80 million conditional loan commitment with Antheia, Inc.
2. Antheia